{"url_path":"/sec/mrkr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1094038/0001104659-26-062763-index.html","accession_number":"0001104659-26-062763","cik":"0001094038","ticker":"MRKR","issuer_name":"Marker Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1094038/0001104659-26-062763-index.html","primary_entity_key":"0001094038","primary_entity_name":"Marker Therapeutics, Inc."},"word_count":599,"has_tables":true,"body_markdown":"**Item 6.         Exhibits**\n\nThe following exhibits are included with this Quarterly Report on Form 10-Q:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n \n\n​\n\n**Incorporated by Reference**\n\n​\n\n​\n\n​\n\n​\n\n**Exhibit**\n**number**\n\n  ​\n\n**Exhibit description**\n\n  ​\n\n**Form**\n\n  ​\n\n**File no.**\n\n  ​\n\n**Exhibit**\n\n  ​\n\n**Filing********date**\n\n  ​\n\n**Filed********herewith**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1\n\n​\n\n[Certificate of Incorporation (Delaware).](https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-4.htm)\n\n​\n\n8-K\n\n​\n\n001-37939\n\n​\n\n3.4\n\n​\n\n10/17/18\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1.1\n\n​\n\n[Certificate of Amendment to Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/1094038/000119312522162322/d480537dex31.htm)\n\n​\n\n8-K\n\n​\n\n001-37939\n\n​\n\n3.1\n\n​\n\n5/27/2022\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1.2\n\n​\n\n[Certificate of Amendment to Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1094038/000110465923007019/tm234466d1_ex3-1.htm)\n\n​\n\n8-K\n\n​\n\n001-37939\n\n​\n\n3.1\n\n​\n\n1/26/2023\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1.3\n\n​\n\n[Certificate of Amendment to Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/tm2613511d1_ex3-1.htm)\n\n​\n\n8-K\n\n​\n\n001-37939\n\n​\n\n3.1\n\n​\n\n5/4/2026\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.2\n\n​\n\n[Bylaws of Marker Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-6.htm)\n\n​\n\n8-K\n\n​\n\n001-37939\n\n​\n\n3.6\n\n​\n\n10/17/18\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n​\n\n[Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended.](mrkr-20260331xex31d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32.1*\n\n​\n\n[Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](mrkr-20260331xex32d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32.2*\n\n​\n\n[Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](mrkr-20260331xex32d2.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n26\n\n[Table of Contents](#TOC)\n\nExhibit 101\n\n​\n\n101.INS - XBRL Instance Document\n\n101.SCH - XBRL Taxonomy Extension Schema Document\n\n101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF - XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB - XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document\n\n104         - Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith).\n\n*\n\nFurnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.\n\n​\n\n**\n\nConfidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.\n\n​\n\n​\n\n27\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nIn accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nDate: May 15, 2026\n\n**MARKER THERAPEUTICS, INC.**\n\n​\n\n​\n\n*/s/ Juan Vera*\n\n​\n\n​\n\n**Juan Vera**\n\n​\n\n​\n\nPresident, Chief Executive Officer and Treasurer (Principal Executive Officer and Principal Financial and Accounting Officer)\n\n​\n\n​\n\n​\n\n​\n\n28"}